{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T01:34:42Z","timestamp":1721352882642},"reference-count":26,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej19-0179","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T22:03:43Z","timestamp":1562882623000},"page":"745-752","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the efficacy and safety of once-daily insulin degludec\/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units\/mL) in insulin-na\u00efve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study"],"prefix":"10.1507","volume":"66","author":[{"given":"Seiya","family":"Shimoda","sequence":"first","affiliation":[{"name":"Division of Food & Health Environmental Sciences, Faculty of Environmental and Symbiotic Sciences, Prefectural University of Kumamoto, Kumamoto 862-8502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakana","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Kumamoto General Hospital, Kumamoto 866-8660, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Hokamura","sequence":"additional","affiliation":[{"name":"Division of Food & Health Environmental Sciences, Faculty of Environmental and Symbiotic Sciences, Prefectural University of Kumamoto, Kumamoto 862-8502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Diabetes, Saiseikai Kumamoto Hospital, Kumamoto 861-4193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Sekigami","sequence":"additional","affiliation":[{"name":"Sekigami Clinic, Division of Medicine & Diabetes and Endocrine, Kumamoto 866-0824, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ichimori","sequence":"additional","affiliation":[{"name":"Ueki Hospital, Kumamoto 861-0136, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iwashita","sequence":"additional","affiliation":[{"name":"Kumamoto Rousai Hospital, Kumamoto 866-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Otsu","sequence":"additional","affiliation":[{"name":"Kumamoto Rousai Hospital, Kumamoto 866-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Yoshimura Clinic, Kumamoto 861-8039, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Sakurado-ri Clinic, Kumamoto 860-0832, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaji","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Kumamoto Chuo Hospital, Kumamoto 862-0962, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357: 1716\u20131730.","DOI":"10.1056\/NEJMoa075392"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193\u2013203.","DOI":"10.2337\/dc08-9025"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, et al. (2015) New insulin glargine 300 Units\u00b7mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units\u00b7mL-1. Diabetes Care 38: 637\u2013643.","DOI":"10.2337\/dc14-0006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Heise T, Nosek L, B\u00f8ttcher SG, Hastrup H, Haahr H (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14: 944\u2013950.","DOI":"10.1111\/j.1463-1326.2012.01638.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, et al. (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14: 859\u2013864.","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, et al. (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15: 175\u2013184.","DOI":"10.1111\/dom.12032"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, et al. (2015) Patient-level meta-analysis of the EDITION 1,2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/mL <i>versus<\/i> glargine 100 U\/mL in people with type 2 diabetes. Diabetes Obes Metab 17: 859\u2013867.","DOI":"10.1111\/dom.12485"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Haahr H, Fita EG, Heise T (2017) A review of insulin degludec\/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet 56: 339\u2013354.","DOI":"10.1007\/s40262-016-0455-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Niskanen L, Leiter LA, Franek E, Weng J, Damci T, et al. (2012) Comparison of a soluble co-formulation of insulin degludec\/insulin aspart <i>vs<\/i> biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 167: 287\u2013294.","DOI":"10.1530\/EJE-12-0293"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, et al. (2014) Comparison of insulin degludec\/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 37: 2084\u20132090.","DOI":"10.2337\/dc13-2908"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Onishi Y, Ono Y, Rab\u00f8l R, Endahl L, Nakamura S (2013) Superior glycaemic control with once-daily insulin degludec\/insulin aspart <i>versus<\/i> insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 15: 826\u2013832.","DOI":"10.1111\/dom.12097"},{"key":"12","unstructured":"12 Editorial Committee for the Treatment Guide for Diabetes (2007) Treatment and diet therapy. In: Japan Diabetes Society (ed) Treatment Guide for Diabetes. Bunkodo, Tokyo, Japan: 21\u201337."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Haneda M, Noda M, Origasa H, Noto H, Yabe D, et al. (2018) Japanese clinical practice guideline for diabetes 2016. Diabetol Int 9: 1\u201345.","DOI":"10.1007\/s13340-018-0345-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Haneda M, Noda M, Origasa H, Noto H, Yabe D, et al. (2018) Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig 9: 657\u2013697.","DOI":"10.1111\/jdi.12810"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) Committee on the standardization of diabetes mellitus-related laboratory testing of the Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 3: 8\u201310.","DOI":"10.1007\/s13340-012-0069-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) Committee on the standardization of diabetes mellitus-related laboratory testing of the Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 3: 39\u201340.","DOI":"10.1111\/j.2040-1124.2012.00207.x"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26: 881\u2013885.","DOI":"10.2337\/diacare.26.3.881"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Workgroup on Hypoglycemia, American Diabetes Association (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28: 1245\u20131249.","DOI":"10.2337\/diacare.28.5.1245"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, et al. (2016) Efficacy and safety of once-daily insulin degludec\/insulin aspart <i>versus<\/i> insulin glargine (U100) for 52 weeks in insulin-na\u00efve patients with type 2 diabetes: a randomized controlled trial. PLoS One 11: e0163350.","DOI":"10.1371\/journal.pone.0163350"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, et al. (2013) A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol 7: 1328\u20131336.","DOI":"10.1177\/193229681300700524"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Nagai Y, Nishine A, Hashimoto E, Nakayama T, Sasaki Y, et al. (2017) Efficacy and safety of switching from basal insulin to once-daily insulin degludec\/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: a 4-week, randomized, open-label, treat-to-target study. J Diabetes Investig 9: 567\u2013572.","DOI":"10.1111\/jdi.12748"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, et al. (2018) More similarities than differences testing insulin glargine 300 units\/mL <i>versus<\/i> insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care 41: 2147\u20132154.","DOI":"10.2337\/dc18-0559"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24 Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, et al. (2012) Insulin degludec <i>versus<\/i> insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35: 2464\u20132471.","DOI":"10.2337\/dc12-1205"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, et al. (2016) New insulin glargine 300 U\/mL <i>versus<\/i> glargine 100 U\/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab 18: 375\u2013383.","DOI":"10.1111\/dom.12619"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, et al. (2016) New insulin glargine 300 U\/mL <i>versus<\/i> glargine 100 U\/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab 18: 366\u2013374.","DOI":"10.1111\/dom.12618"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27 Yamabe M, Kuroda M, Hirosawa Y, Kamino H, Ohno H, et al. (2019) Comparison of insulin glargine 300 U\/mL and insulin degludec using flash glucose monitoring: a randomized cross-over study. J Diabetes Investig 10: 352\u2013357.","DOI":"10.1111\/jdi.12894"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ19-0179\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T18:31:22Z","timestamp":1663957882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ19-0179\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0179","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}